Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.

Oncology reports - 1 May 2022

Forgione Michelle O, McClure Barbara J, Page Elyse C, Yeung David T, Eadie Laura N, White Deborah L

Abstract excerpt

The presence of a TP53 mutation is a predictor of poor outcome in leukaemia, and efficacious targeted therapies for these patients are lacking. The curaxin CBL0137 has demonstrated promising antitumour activities in multiple cancers such as glioblastoma, acting through p53 activation, NF‑κB inhibition and chromatin remodelling. In the present study, it was revealed using Annexin‑V/7‑AAD apoptosis assays that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Glioblastoma
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 35323988
DOI: 10.3892/or.2022.8310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.PMID 35323988Read ↗

Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.Semantic proximity Read ↗

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.Semantic proximity Read ↗

<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaSemantic proximity Read ↗

<i>BIRC5</i> dependency defines a targetable vulnerability in <i>TP53</i> mutant acute myeloid leukemiaSemantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemiaSemantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity Read ↗

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsSemantic proximity Read ↗

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read ↗

p53 partial loss-of-function mutations sensitize to chemotherapySemantic proximity Read ↗

Small-molecule MDM2 inhibitor LQFM030-induced apoptosis in p53-null K562 chronic myeloid leukemia cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.